KYMERA THERAPEUTICS, INC. Payments for Repurchase of Initial Public Offering
KYMERA THERAPEUTICS, INC. (KYMR) reported Payments for Repurchase of Initial Public Offering of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfInitialPublicOffering · last filed 2024-02-22
- KYMERA THERAPEUTICS, INC. payments for repurchase of initial public offering for the quarter ending 2021-12-31 was $0.00.
- KYMERA THERAPEUTICS, INC. payments for repurchase of initial public offering for the quarter ending 2021-09-30 was $0.00.
- KYMERA THERAPEUTICS, INC. payments for repurchase of initial public offering for the quarter ending 2021-06-30 was $0.00.
- KYMERA THERAPEUTICS, INC. payments for repurchase of initial public offering for the quarter ending 2021-03-31 was $397.00K.
- KYMERA THERAPEUTICS, INC. payments for repurchase of initial public offering for fiscal 2023 was $0.00.
- KYMERA THERAPEUTICS, INC. payments for repurchase of initial public offering for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- KYMERA THERAPEUTICS, INC. payments for repurchase of initial public offering for fiscal 2021 was $397.00K.
| Period end | Payments for Repurchase of Initial Public Offering 3 month | Payments for Repurchase of Initial Public Offering 6 month | Payments for Repurchase of Initial Public Offering 9 month | Payments for Repurchase of Initial Public Offering 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-22 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-02-22 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $397.00K 10-K · filed 2024-02-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $397.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $397.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $397.00K 10-Q · filed 2022-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |